Genitourinary Syndrome of Menopause (GSM): How Common Is It, and Why Are Most Women Not Getting Help?

What Is GSM, and Why Did the Name Change?

Genitourinary Syndrome of Menopause is the umbrella term that replaced the older labels "vulvovaginal atrophy" and "atrophic vaginitis" in 2014, after a joint nomenclature committee convened by The Menopause Society (NAMS) and the International Society for the Study of Women's Sexual Health (ISSWSH) agreed the old terms were anatomically incomplete and stigmatizing.

The name change mattered clinically. GSM recognizes that estrogen loss affects not just the vaginal epithelium but the entire lower urogenital tract: the vulva, urethra, bladder trigone, and pelvic floor. Symptoms that a woman might separately report to different specialists, such as urinary urgency to a urologist and dyspareunia to a gynecologist, are frequently one syndrome driven by the same underlying estrogen deficiency.

What counts as GSM for epidemiologic purposes?

This question is where global prevalence estimates diverge most sharply. Some studies use patient-reported symptoms alone. Others require physical examination findings such as reduced vaginal rugae, pale epithelium, or elevated vaginal pH above 5.0. A few require both. The Menopause Society's 2023 position statement on GSM defines GSM by the presence of at least one genitourinary symptom attributable to estrogen deficiency in the absence of another cause. Because no gold-standard diagnostic test exists, prevalence figures across studies are not directly comparable.

The shift from "atrophy" to a syndrome framework

Calling this a syndrome, not an atrophy, also changed how clinicians should screen. A woman who presents only with urinary urgency or recurrent urinary tract infections after menopause may have GSM as the root cause, not a primary bladder disorder. Recognizing that constellation is why epidemiologists now track the full symptom cluster rather than vaginal dryness alone.

Global Prevalence: What the Numbers Actually Show

The most widely cited figure is that approximately 50 to 60 percent of postmenopausal women experience at least one GSM symptom, based on pooled data from studies published before 2015. The range is wide: estimates run from 27 percent in populations where women are less likely to report sexual symptoms to 84 percent in clinic-based samples where structured questionnaires are used.

The REVIVE survey (2014 to 2015)

The Real Women's Views of Treatment Options for Menopausal Vaginal Changes (REVIVE) survey, which enrolled 3,046 postmenopausal women in the United States, found that 62 percent reported vaginal symptoms they attributed to menopause, and 59 percent reported that symptoms affected their quality of life. Nearly half said symptoms had worsened over time, yet only 7 percent were currently using a prescription vaginal estrogen.

European and Asia-Pacific data

A multinational European study of postmenopausal women found vaginal dryness prevalence of 39 percent in France, 32 percent in Germany, and 46 percent in Sweden, illustrating meaningful country-level variation that likely reflects both biology and cultural willingness to report symptoms. In Asia-Pacific populations, prevalence data are sparser. A 2020 review in the journal Menopause found that reported GSM symptom rates across Asian populations ranged from 18 to 52 percent, with under-reporting suspected to be especially high given cultural norms around discussing sexual health.

Latin America and sub-Saharan Africa

Population-level data from Latin America and sub-Saharan Africa remain limited, a gap acknowledged explicitly by the authors of the 2022 Global Consensus Statement on Menopause published in Climacteric. What evidence exists suggests comparable or higher symptom burden but substantially lower treatment access.

A practical way to interpret the global range is to separate three distinct measurement contexts:

| Study context | Typical prevalence estimate | |---|---| | Population survey, self-report only | 27 to 45% | | Structured questionnaire, community sample | 50 to 65% | | Clinic-based sample, physical exam included | 70 to 84% |

The clinic-based figures are higher partly because women with symptoms are more likely to seek care, but they also reflect that physical signs are often present even when women have not yet named their experience as a medical problem.

Prevalence by Life Stage: Not Just a Postmenopause Story

Perimenopause: symptoms begin earlier than most women expect

GSM does not switch on at the final menstrual period. Estrogen fluctuates and trends downward throughout perimenopause, which can last four to eight years for many women. Vaginal dryness and urinary symptoms have been documented in women who are still menstruating irregularly. The SWAN (Study of Women's Health Across the Nation) cohort, which followed over 3,000 midlife women across racial and ethnic groups longitudinally, found that vaginal dryness increased from approximately 4 percent in early perimenopause to 21 percent in late perimenopause, even before the final menstrual period.

This matters because it shifts the clinical window. Waiting until a woman has been in menopause for a year or more before discussing GSM means missing an opportunity to manage symptoms when they are milder and potentially easier to treat.

Early surgical or medical menopause

Women who undergo bilateral oophorectomy, chemotherapy, or pelvic radiation experience an abrupt loss of estrogen at whatever age the treatment occurs. GSM symptoms in this group can be severe and rapid in onset. Approximately 50,000 bilateral oophorectomies are performed annually in the United States in premenopausal women for cancer risk reduction or other indications, making surgical menopause a substantial contributor to overall GSM burden in women under 50.

Women with estrogen-receptor-positive breast cancer who are treated with aromatase inhibitors face a particularly difficult situation: their GSM is often more severe than natural menopause because estrogen suppression is near-complete, and the treatment itself is a contraindication to systemic estrogen therapy. Up to 80 percent of women on aromatase inhibitors report significant GSM symptoms, and this is a driver of treatment non-adherence to the cancer therapy itself.

Postmenopause: progressive if untreated

Unlike vasomotor symptoms such as hot flashes, which tend to decrease in frequency for most women over three to five years, GSM worsens over time without treatment. Tissues become progressively more atrophic, vaginal pH rises further, and the risk of recurrent urinary tract infections increases. Women who are more than ten years past their final menstrual period have measurably higher rates of dyspareunia and vaginal atrophy signs on examination compared to those who are two to five years postmenopausal. This progressive course is a core reason treatment guidelines recommend long-term, not short-course, management.

Postpartum and lactation: a life stage often missed

Breastfeeding suppresses estrogen via elevated prolactin. Postpartum women who are fully breastfeeding can experience vaginal dryness, dyspareunia, and urinary symptoms that are physiologically identical to GSM, despite being decades away from menopause. Estrogen levels in lactating women can be comparable to those seen in early postmenopause. This is rarely labeled GSM in clinical practice, but the same low-dose topical estrogen options used in postmenopausal women have been used off-label in breastfeeding women with severe symptoms, with the caveat that systemic absorption should remain minimal. Women in this life stage should discuss options with their clinician before starting any hormonal preparation.

Why Is GSM So Dramatically Undertreated?

The gap between prevalence and treatment is one of the most documented, and most frustrating, patterns in women's health. Estimates consistently show that fewer than 25 percent of symptomatic women receive any prescription treatment, and over-the-counter lubricant use does not fully substitute for tissue-level treatment.

Women do not bring it up

In the REVIVE survey, 70 percent of symptomatic women had not discussed their symptoms with a clinician in the past year. Reasons cited most often were embarrassment, an assumption that symptoms were a normal and untreatable part of aging, and not wanting to raise the topic unless a doctor asked first.

Clinicians do not ask

A 2019 survey of primary care providers published in Menopause found that fewer than half routinely screened postmenopausal patients for GSM symptoms, and many reported uncertainty about which treatments were safe and appropriate, particularly in women with a history of breast cancer. This is a systems-level failure that compounds individual under-reporting.

The "it's just aging" narrative

Women absorb the message that vaginal dryness after menopause is simply what happens, not a treatable medical condition. This framing is clinically inaccurate. GSM is a hormone-deficiency state with effective, evidence-supported treatments ranging from low-dose local vaginal estrogen to ospemifene (a selective estrogen receptor modulator taken orally) to vaginal DHEA (prasterone). None of these require that a woman also use systemic hormone therapy.

PCOS, Premature Ovarian Insufficiency, and Other Conditions That Affect GSM Risk

Several conditions specific to women's reproductive health alter the age at which GSM develops or its severity.

Premature ovarian insufficiency (POI)

Women with POI, defined as ovarian dysfunction before age 40, experience estrogen deficiency for a longer cumulative lifetime than women who reach natural menopause at 51 to 52 years. The ACOG Practice Bulletin on POI (2023) recommends hormone therapy in these women until at least the average age of natural menopause both for GSM prevention and for cardiovascular and bone health. Left untreated, GSM in women with POI can be present for three to four decades.

PCOS and late reproductive years

Women with PCOS often have relatively higher androgen levels that may provide some partial vaginal mucosal protection compared to women without PCOS, but the evidence on whether PCOS alters GSM risk at menopause is limited and mixed. What is clear is that PCOS does not protect women from menopause-related estrogen loss when it eventually occurs.

Endometriosis and surgical history

Women who have undergone surgical menopause because of endometriosis, often at younger ages, are at high risk of early and severe GSM. In this group, decisions about hormone therapy are complex because endometriosis is estrogen-sensitive; combined estrogen-progestogen therapy is generally recommended rather than estrogen alone when the uterus is absent after surgery for endometriosis, to reduce the theoretical risk of recurrence stimulation.

The Evidence Gap: Who Is Missing from the Data?

Women have been historically underrepresented in clinical trials, and within women's health research, the gaps are uneven. Most GSM epidemiology studies have over-represented white, educated, North American or Northern European women. The SWAN cohort is an important exception, deliberately enrolling Black, Hispanic, Chinese, and Japanese American women, and its data show that symptom reporting and health-seeking behavior differ substantially across racial groups even when biological rates of menopause-related estrogen change are similar.

The data are thinner still for transgender men who have retained ovarian function, women in low- and middle-income countries, and women with disabilities that affect communication or access to gynecologic care. Any clinician or researcher quoting a single global prevalence figure should acknowledge that this figure is at best a weighted average across populations with very different detection and reporting conditions.

What the Trends Show: Is GSM Becoming More Recognized?

The terminology change from vulvovaginal atrophy to GSM in 2014 was intended to increase recognition, and there is some evidence it has worked. A bibliometric analysis found that peer-reviewed publications using the term "genitourinary syndrome of menopause" increased more than fivefold between 2014 and 2022. Awareness among patients, measured in the 2019 CLOSER (Clarifying Vaginal Atrophy's Impact on Sex and Relationships) survey, remained low: fewer than 10 percent of postmenopausal women were familiar with the term GSM, and the majority still used the phrase "vaginal dryness" if they named their symptoms at all.

Treatment rates have improved modestly. Non-hormonal options, including vaginal moisturizers used regularly and lubricants used at the time of intercourse, have grown in use as over-the-counter access is easy and stigma is lower for these products. But a 2023 Menopause Society clinical practice statement notes that non-hormonal options primarily address symptom comfort and do not reverse the underlying tissue changes the way low-dose local estrogen does. Treatment rates for prescription options remain below where the clinical need would predict them to be.

Who Is Most Affected, and What the Severity Data Show

Symptom burden is not uniform. Dyspareunia (painful sex) is reported by approximately 45 percent of postmenopausal women, making it the GSM symptom most consistently associated with negative quality-of-life impact in validated instruments such as the Day-to-Day Impact of Vaginal Aging (DIVA) questionnaire. Urinary symptoms, including urgency, frequency, and recurrent UTIs, are reported by 15 to 30 percent of postmenopausal women and are frequently attributed to aging alone rather than to GSM.

Women who are not sexually active are not protected from symptom burden. Vaginal dryness, irritation, and urinary symptoms occur independent of sexual activity and affect daily comfort, exercise tolerance, and ability to undergo pelvic examination comfortably.

Practical Takeaway for Your Next Clinical Conversation

If you are in perimenopause or postmenopause and you are experiencing any combination of vaginal dryness, burning, irritation, painful sex, or new urinary urgency, these symptoms are not inevitable and untreatable. They reflect a specific, well-understood physiological change, and effective options exist at every severity level.

Ask your clinician directly: "Could this be GSM, and what are my treatment options given my history?" If your clinician does not screen you at your annual visit, bring it up yourself. The data are clear that clinicians rarely ask, and symptoms rarely improve on their own.

The Menopause Society's "Find a Provider" tool at menopause.org can help you locate a clinician with specific menopause training if your current provider is not comfortable managing GSM.